New England Research & Management, Inc. Alkermes Plc. Call Options Transaction History
New England Research & Management, Inc.
- $197 Million
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALKS
# of Institutions
410Shares Held
177MCall Options Held
229KPut Options Held
436K-
Black Rock Inc. New York, NY29.1MShares$852 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.2MShares$533 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.8MShares$345 Million0.05% of portfolio
-
State Street Corp Boston, MA8.02MShares$235 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.88MShares$201 Million3.72% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.81B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...